Fintel reports that on September 25, 2026, Barclays initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNDZ) with a Overweight recommendation. This analyst action is accompanied by other recent updates from various firms. On September 24, 2026, HC Wainwright & Co. reiterated its Buy rating on the company, maintaining its prior rating of Buy. Additionally, on September 23, 2026, Citigroup maintained its Buy rating, keeping its prior rating of Buy.

The broader analyst consensus presents a distinct set of target price and recommendation metrics. As of February 24, 2026, the current consensus target mean is $0.00 and the median is $0.00. This reflects a consensus target revision percent of -76.23% from the prior consensus target mean of $0.01 recorded on January 14, 2026. For the current recommendation period of September 1, 2026, the current recommendation total is 16, consisting of 7 strong buy, 8 buy, and 1 hold recommendations. This translates to a current positive percentage of 93.8% and a hold percentage of 6.3%. In the prior recommendation period of August 1, 2026, the total recommendation count was 15, which included 6 strong buy, 8 buy, and 1 hold recommendations, representing a positive percentage of 93.3% and a hold percentage of 6.7%.

Ligand Pharmaceuticals Incorporated, based in the United States, operates primarily within the biopharmaceutical industry. The company specializes in the development and licensing of technologies that assist other pharmaceutical companies in discovering and developing medications. One of its flagship offerings is the Captisol technology, which enhances the solubility, stability, and bioavailability of active pharmaceutical ingredients. Ligand’s business model focuses heavily on forming partnerships through license agreements, enabling them to leverage their technology platforms across various drug candidates and therapeutic areas. Their portfolio is diverse, including partnerships in areas such as oncology, neurology, and infectious diseases, which underscore their broad impact on drug development across the pharmaceutical industry.

Recent analyst actions

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.